Brookline Cap M Weighs in on Immunic FY2025 Earnings

Immunic, Inc. (NASDAQ:IMUX) – Stock analysts at Brookline Cap M issued their FY2025 earnings per share (EPS) estimates for shares of Immunic in a research note issued to investors on Tuesday, February 3rd. Brookline Cap M analyst F. Ahmed forecasts that the company will post earnings per share of ($0.65) for the year. Brookline Cap M currently has a “Strong-Buy” rating on the stock. The consensus estimate for Immunic’s current full-year earnings is ($0.94) per share. Brookline Cap M also issued estimates for Immunic’s Q4 2025 earnings at ($0.12) EPS, Q1 2026 earnings at ($0.13) EPS, Q2 2026 earnings at ($0.12) EPS, Q3 2026 earnings at ($0.11) EPS, Q4 2026 earnings at ($0.10) EPS and FY2026 earnings at ($0.46) EPS.

A number of other equities analysts have also recently issued reports on IMUX. D. Boral Capital reissued a “buy” rating and issued a $8.00 target price on shares of Immunic in a report on Wednesday, January 7th. LADENBURG THALM/SH SH upgraded shares of Immunic to a “strong-buy” rating in a research note on Thursday, October 16th. Brookline Capital Acquisition upgraded shares of Immunic to a “strong-buy” rating in a research report on Tuesday. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Immunic in a report on Monday, December 29th. Finally, Roth Mkm assumed coverage on Immunic in a research report on Friday, November 7th. They set a “buy” rating and a $3.00 price target on the stock. Four investment analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $7.40.

Immunic Stock Up 5.3%

Shares of IMUX stock opened at $0.62 on Friday. The business’s 50 day moving average is $0.63 and its two-hundred day moving average is $0.77. The company has a market cap of $74.58 million, a PE ratio of -0.75 and a beta of 1.58. Immunic has a 12 month low of $0.51 and a 12 month high of $1.39.

Immunic (NASDAQ:IMUX) last released its quarterly earnings data on Thursday, November 13th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.05.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the company. Qube Research & Technologies Ltd acquired a new stake in shares of Immunic in the third quarter valued at approximately $29,000. Two Sigma Investments LP acquired a new position in Immunic during the third quarter valued at approximately $52,000. HB Wealth Management LLC acquired a new stake in shares of Immunic in the 3rd quarter valued at $81,000. Virtu Financial LLC bought a new stake in shares of Immunic during the 3rd quarter worth $99,000. Finally, GSA Capital Partners LLP acquired a new position in Immunic during the third quarter worth about $170,000. 51.82% of the stock is currently owned by institutional investors.

Immunic News Roundup

Here are the key news stories impacting Immunic this week:

• Positive Sentiment: Brookline Capital Management upgraded Immunic to a “Strong‑Buy” (reported by Zacks), a direct positive catalyst that can attract buyers and short‑covering. Zacks Upgrade
• Positive Sentiment: Brookline’s FY2026 outlook is materially less negative than the consensus — the firm forecasts FY2026 EPS of ($0.46) versus the street consensus of about ($0.94) — signaling an improving earnings trajectory that may be interpreted positively by investors. MarketBeat Report
• Neutral Sentiment: Brookline published detailed quarterly EPS forecasts (Q4 2025: -$0.12; Q1 2026: -$0.13; Q2 2026: -$0.12; Q3 2026: -$0.11; Q4 2026: -$0.10), providing investors with updated cadence for expected losses and potential milestones to watch. MarketBeat Forecasts
• Negative Sentiment: Despite the upgrade and smaller projected losses, Immunic remains unprofitable with consensus and Brookline forecasts still negative; the company’s small market cap, low share price and relatively thin liquidity increase execution and stock‑volatility risk for investors.

About Immunic

Immunic, Inc is a clinical-stage biopharmaceutical company focused on developing novel oral therapies to treat chronic inflammatory and autoimmune diseases as well as certain cancers. The company’s research strategy centers on small-molecule immunology, aiming to offer targeted treatments with improved safety and tolerability profiles. By modulating key signaling pathways within the immune system, Immunic seeks to address underlying disease mechanisms and achieve durable therapeutic benefits for patients.

Immunic’s lead product candidate, vidofludimus calcium (IMU-838), is an oral selective dihydroorotate dehydrogenase (DHODH) inhibitor in Phase 2 clinical development for conditions including ulcerative colitis, Crohn’s disease and relapsing multiple sclerosis.